Axogen Inc. is an American biotechnology company based in Alachua, Florida, that works to develop a range of innovative surgical solutions designed to repair peripheral nerve damage and restore nerve function in patients suffering post-injury or post-surgery nerve damage issues. Founded in 2002, the firm serves an international audience, although not all products are available in all countries.
Among the company’s patented products are the Avance Nerve Graft, designed to repair peripheral nerve discontinuities; the Axoguard Nerve Connector, which aims to repair severed peripheral nerves; and the Axoguard Nerve Protector, which is designed to protect injured nerves and reinforce nerve reconstruction while preventing soft tissue attachments. Axogen technology is utilised with a wide range of patients, from the victims of gunshot wounds to post-mastectomy patients.
The company supports a range of clinical studies and research programmes aimed at further understanding peripheral nerve repair and provides resources to raise awareness and provide education on the issues involved in nerve damage and nerve repair. The firm has been trading on the NASDAQ since its public launch in 2013 and is listed under the ticker AXGN.
To receive news and updates on the AXGN share price, simply add this stock to your eToro watchlist.